Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $5.84 Consensus Target Price from Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have earned an average rating of “Hold” from the six analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $5.84.

A number of brokerages have recently weighed in on ZNTL. Wells Fargo & Company dropped their target price on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, August 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright upgraded Zentalis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 7th. Finally, Wall Street Zen upgraded Zentalis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, August 9th.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd acquired a new position in Zentalis Pharmaceuticals in the second quarter worth approximately $31,000. Cerity Partners LLC increased its holdings in Zentalis Pharmaceuticals by 58.7% in the first quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock worth $33,000 after buying an additional 7,579 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in Zentalis Pharmaceuticals in the second quarter worth approximately $37,000. Y Intercept Hong Kong Ltd acquired a new position in Zentalis Pharmaceuticals in the second quarter worth approximately $38,000. Finally, Corient Private Wealth LLC acquired a new position in Zentalis Pharmaceuticals in the second quarter worth approximately $41,000.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL opened at $1.63 on Monday. The company has a market capitalization of $117.59 million, a price-to-earnings ratio of -0.72 and a beta of 1.77. Zentalis Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $4.44. The business’s 50-day moving average is $1.61 and its 200-day moving average is $1.43.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Wednesday, August 6th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.19. Equities research analysts expect that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.